Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 288

Results For "CRE"

4819 News Found

Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr
News | May 03, 2023

Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr

The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year


IMCD Colombia acquires pharma API distributor Allianz
Supply Chain | May 03, 2023

IMCD Colombia acquires pharma API distributor Allianz

Allianz is ISO 9001:2015 certified and INVIMA certified for storage, sampling, dispensation, and distribution of APIs to the Colombian market


Healthium Medtech appoints Prashant Krishnan as Global Business Head for Advanced Wound Care and Surgery
People | May 02, 2023

Healthium Medtech appoints Prashant Krishnan as Global Business Head for Advanced Wound Care and Surgery

The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis


Majority of UK physicians believe Brexit aggravated NHS staff shortage crisis: GlobalData
News | May 02, 2023

Majority of UK physicians believe Brexit aggravated NHS staff shortage crisis: GlobalData

Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis


Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr
News | April 30, 2023

Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr

Specialty Chemicals grew 38% YoY for FY23


Atul appoints Rangaswamy Iyer as Independent Director
People | April 29, 2023

Atul appoints Rangaswamy Iyer as Independent Director

The appointment is effective from May 01, 2023 for five years


TPAG organizes Thalassemia & SCD prevention discussion
News | April 29, 2023

TPAG organizes Thalassemia & SCD prevention discussion

The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally


Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
News | April 28, 2023

Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr

Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects


Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData
News | April 28, 2023

Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData

Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.